Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and SingaporeBusiness Wire • 01/10/25
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and SingaporeBusiness Wire • 01/10/25
Vertex Pharmaceuticals Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Vertex Pharmaceuticals (VRTX)Accesswire • 01/09/25
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)PRNewsWire • 01/07/25
Levi & Korsinsky Reminds Vertex Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VRTXAccesswire • 01/02/25
Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTXAccesswire • 12/31/24
Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?Zacks Investment Research • 12/30/24
Levi & Korsinsky Reminds Shareholders of an Investigation into Vertex Pharmaceuticals Incorporated (VRTX) Regarding Potential Securities Fraud AllegationsAccesswire • 12/27/24
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the DipThe Motley Fool • 12/26/24
Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud ViolationsAccesswire • 12/26/24
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13Business Wire • 12/23/24
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekZacks Investment Research • 12/23/24
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish AnalystBenzinga • 12/23/24
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?The Motley Fool • 12/22/24
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered StockInvestors Business Daily • 12/20/24